Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Yinhsuan Michely Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Experimental Medicine, McGill University. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Nanoparticles, Receptor, IGF Type 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministère de l'Economie et de l'Innovation du Québec, Ministère de l’Economie et de l’Innovation du Québec.
Abstract (Originalsprache)
Background
Glioblastoma is an aggressive brain cancer with a 5-year survival rate of 5–10%. Current therapeutic options are limited, due in part to drug exclusion by the blood–brain barrier, restricting access of targeted drugs to the tumor. The receptor for the type 1 insulin-like growth factor (IGF-1R) was identified as a therapeutic target in glioblastoma. We previously reported that the intracerebral growth of glioma cells with reduced IGF-1R levels was inhibited. The objectives of this study were to evaluate the sensitivity of glioma cells to a novel IGF-axis inhibitor, the IGF-Trap, and optimize its delivery to the brain.
Methods
We tested the effect of the IGF-Trap on the growth of the human glioma stem cells MES-1123 and U87 MG cells, and of murine GL261 cells in vivo, using subcutaneous and orthotopic implantation.
Results
We show that the growth of glioma cells implanted subcutaneously or orthotopically in the brain was inhibited by systemic and direct intracerebral administration of IGF-Trap, respectively, resulting in increased survival. To increase the efficiency of systemic delivery to the brain, we encapsulated the IGF-Trap in trimethyl chitosan (TRIOZAN™) nanoparticles prior to intravenous injection. We found that nanoparticle encapsulation increased the uptake and retention of the IGF-Trap in the brain and resulted in an improved therapeutic effect against intra-cerebrally growing tumors.
Conclusion
Our results identify the IGF-Trap as a potent inhibitor of intracerebral glioma growth and show that encapsulation in nanoparticles can improve delivery of biologics such as the IGF-Trap to the brain, thereby enhancing the therapeutic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Experimental Medicine, McGill University.
- The Research Institute of the McGill University Health Center, Montreal, QC, Canada H4A 3J1.
- Department of Surgery.
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Pediatrics.
- Ovensa Innovations Inc, 500 Blvd Cartier O, Laval, QC, CanadaH7V 5B7.
ORCID-Profile: Pnina Brodt
Förderung
- Ministère de l'Economie et de l'Innovation du Québec
- Ministère de l’Economie et de l’Innovation du Québec
Zitieren
APA
Chen, Y. M., Chambon, J., Moquin, A., Hashimoto, M., Perrino, S., Leibovitch, M., Benslimane, Y., Haçariz, O., Yang, Q., Nakano, I., Meehan, B., Rak, J., Gagné, S., & Brodt, P. (2025). Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf011
Vancouver
Chen YM, Chambon J, Moquin A, Hashimoto M, Perrino S, Leibovitch M, et al. Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf011
BibTeX
@article{Chen2025,
author = {Chen, Yinhsuan Michely and Chambon, Julien and Moquin, Alexandre and Hashimoto, Masakazu and Perrino, Stephanie and Leibovitch, Matthew and Benslimane, Yasmine and Haçariz, Orçun and Yang, Qin and Nakano, Ichiro and Meehan, Brian and Rak, Janusz and Gagné, Stéphane and Brodt, Pnina},
title = {Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf011}
}
EUVIMED